Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo - PubMed (original) (raw)

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

M Fràter-Schröder et al. Proc Natl Acad Sci U S A. 1987 Aug.

Abstract

Tumor necrosis factor type alpha (TNF-alpha) inhibits endothelial cell proliferation in vitro. Basal cell growth (in the absence of exogenously added growth factor) and fibroblast growth factor (FGF)-stimulated cell proliferation are inhibited in a dose-dependent manner from 0.1 to 10 ng/ml with half-maximal inhibition occurring at 0.5-1.0 ng of TNF-alpha per ml. Bovine aortic and brain capillary endothelial and smooth muscle cells are similarly affected. TNF-alpha is a noncompetitive antagonist of FGF-stimulated cell proliferation. Its action on endothelial cells is reversible and noncytotoxic. Surprisingly, TNF-alpha does not seem to inhibit endothelial cell proliferation in vivo. In the rabbit cornea, even a high dose of TNF-alpha (10 micrograms) does not suppress angiogenesis induced by basic FGF. On the contrary, in this model system TNF-alpha stimulates neovascularization. The inflammatory response that is seen in the cornea after TNF-alpha implantation suggests that the angiogenic properties of this agent may be a consequence of leukocyte infiltration.

PubMed Disclaimer

Similar articles

Cited by

References

    1. EMBO J. 1985 Aug;4(8):1951-6 - PubMed
    1. Science. 1985 Nov 22;230(4728):943-5 - PubMed
    1. J Exp Med. 1985 Dec 1;162(6):2163-8 - PubMed
    1. Jpn J Cancer Res. 1985 Oct;76(10):989-94 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Jan;83(2):446-50 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources